Skip to main content
Top
Published in: Malaria Journal 1/2020

Open Access 01-12-2020 | Chloroquin | Research

Correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds

Authors: Dao Ngoc Hien Tam, Gehad Mohamed Tawfik, Amr Ehab El-Qushayri, Ghaleb Muhammad Mehyar, Sedralmontaha Istanbuly, Sedighe Karimzadeh, Vo Linh Tu, Ranjit Tiwari, Truong Van Dat, Phuong Thuy Viet Nguyen, Kenji Hirayama, Nguyen Tien Huy

Published in: Malaria Journal | Issue 1/2020

Login to get access

Abstract

Background

Despite noticeable improvement in anti-malarial treatment, rapid growth of resistant malaria strains points out the need for continuous development of novel anti-malarials to fight the disastrous infection. Haemozoin is considered as a novel inhibitory pathway for new anti-malarial drugs, therefore, this study aimed to systematically review all articles investigating the correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds.

Methods

A literature search was conducted on 22 October 2017 in eight databases for relevant in vitro articles reporting the correlation between anti-malarial and anti-haemozoin of anti-malarial compounds, based on the constructed search terms and inclusion criteria. ToxRtool was used to assess quality of each study.

Results

A total of ten articles were included in the review. In vitro anti-malarial and anti-haemozoin activity had a good correlation for quinolines for sensitive strains (R2 ranging from 0.66 to 0.95) and xanthones (Spearman ρ = 0.886). However, these correlations were reached after removing some compounds which had non-detectable anti-malarial or anti-haemozoin effects. Other structures (acridines, pyrolidines) showed negligible correlation with Spearman ρ ranging from 0.095 to 0.381 for acridines, and r varying from 0.54 to 0.62 for pyrolidines. Some good correlations were only shown in a logarithmic manner or when the anti-malarial activity was normalized.

Conclusion

The results raised a relative relationship between anti-haemozoin and in vitro anti-malarial activities. Some studies reported compounds that were effective in the inhibition of haemozoin formation, but failed to inhibit the parasite survival and vice versa. The correlation results in these studies were calculated after these compounds were removed from their analysis. The ability of anti-malarial compounds to accumulate inside the reaction site might strengthen their anti-malarial activity.
Appendix
Available only for authorised users
Literature
1.
go back to reference Müller IB, Hyde JE. Antimalarial drugs: modes of action and mechanisms of parasite resistance. Future Microbiol. 2010;5:1857–73.CrossRef Müller IB, Hyde JE. Antimalarial drugs: modes of action and mechanisms of parasite resistance. Future Microbiol. 2010;5:1857–73.CrossRef
2.
go back to reference Sutherland CJ, Tanomsing N, Nolder D, Oguike M, Jennison C, Pukrittayakamee S, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis. 2010;201:1544–50.CrossRef Sutherland CJ, Tanomsing N, Nolder D, Oguike M, Jennison C, Pukrittayakamee S, et al. Two nonrecombining sympatric forms of the human malaria parasite Plasmodium ovale occur globally. J Infect Dis. 2010;201:1544–50.CrossRef
3.
go back to reference Turschner S, Efferth T. Drug resistance in Plasmodium: natural products in the fight against malaria. Mini Rev Med Chem. 2009;9:206–14.CrossRef Turschner S, Efferth T. Drug resistance in Plasmodium: natural products in the fight against malaria. Mini Rev Med Chem. 2009;9:206–14.CrossRef
4.
go back to reference Mockenhaupt FP, Ehrhardt S, Burkhardt J, Bosomtwe SY, Laryea S, Anemana SD, et al. Manifestation and outcome of severe malaria in children in northern Ghana. Am J Trop Med Hyg. 2004;71:167–72.CrossRef Mockenhaupt FP, Ehrhardt S, Burkhardt J, Bosomtwe SY, Laryea S, Anemana SD, et al. Manifestation and outcome of severe malaria in children in northern Ghana. Am J Trop Med Hyg. 2004;71:167–72.CrossRef
5.
go back to reference Parhizgar AR, Tahghighi A. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iran J Med Sci. 2017;42:115–28.PubMedPubMedCentral Parhizgar AR, Tahghighi A. Introducing new antimalarial analogues of chloroquine and amodiaquine: a narrative review. Iran J Med Sci. 2017;42:115–28.PubMedPubMedCentral
6.
go back to reference Bhattarai A, Ali AS, Kachur SP, Mårtensson A, Abbas AK, Khatib R, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 2007;4:e309.CrossRef Bhattarai A, Ali AS, Kachur SP, Mårtensson A, Abbas AK, Khatib R, et al. Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 2007;4:e309.CrossRef
7.
go back to reference Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRef Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRef
8.
go back to reference Goyal M, Singh P, Alam A, Das SK, Iqbal MS, Dey S, et al. Aryl aryl methyl thio arenes prevent multidrug-resistant malaria in mouse by promoting oxidative stress in parasites. Free Radic Biol Med. 2012;53:129–42.CrossRef Goyal M, Singh P, Alam A, Das SK, Iqbal MS, Dey S, et al. Aryl aryl methyl thio arenes prevent multidrug-resistant malaria in mouse by promoting oxidative stress in parasites. Free Radic Biol Med. 2012;53:129–42.CrossRef
9.
go back to reference Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci. 2011;366:2806–14.CrossRef Hill AV. Vaccines against malaria. Philos Trans R Soc Lond B Biol Sci. 2011;366:2806–14.CrossRef
10.
go back to reference Wang R, Smith JD, Kappe SH. Advances and challenges in malaria vaccine development. Expert Rev Mol Med. 2009;11:e39.CrossRef Wang R, Smith JD, Kappe SH. Advances and challenges in malaria vaccine development. Expert Rev Mol Med. 2009;11:e39.CrossRef
11.
go back to reference Alam A, Goyal M, Iqbal MS, Pal C, Dey S, Bindu S, et al. Novel antimalarial drug targets: hope for new antimalarial drugs. Expert Rev Clin Pharmacol. 2009;2:469–89.CrossRef Alam A, Goyal M, Iqbal MS, Pal C, Dey S, Bindu S, et al. Novel antimalarial drug targets: hope for new antimalarial drugs. Expert Rev Clin Pharmacol. 2009;2:469–89.CrossRef
12.
13.
go back to reference Jacobs L, de Kock C, de Villiers KA, Smith PJ, Smith VJ, van Otterlo WA, et al. Design, synthesis, and evaluation of novel ferroquine and phenylequine analogues as potential antiplasmodial agents. ChemMedChem. 2015;10:2099–110.CrossRef Jacobs L, de Kock C, de Villiers KA, Smith PJ, Smith VJ, van Otterlo WA, et al. Design, synthesis, and evaluation of novel ferroquine and phenylequine analogues as potential antiplasmodial agents. ChemMedChem. 2015;10:2099–110.CrossRef
14.
go back to reference White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–4.CrossRef White NJ. Qinghaosu (artemisinin): the price of success. Science. 2008;320:330–4.CrossRef
15.
go back to reference Orjih AU. On the mechanism of hemozoin production in malaria parasites: activated erythrocyte membranes promote β-hematin synthesis. Exp Biol Med. 2001;226:746–52.CrossRef Orjih AU. On the mechanism of hemozoin production in malaria parasites: activated erythrocyte membranes promote β-hematin synthesis. Exp Biol Med. 2001;226:746–52.CrossRef
16.
go back to reference Pauling L, Coryell CD. The magnetic properties and structure of hemoglobin, oxyhemoglobin and carbonmonoxyhemoglobin. Proc Natl Acad Sci USA. 1936;22:210–6.CrossRef Pauling L, Coryell CD. The magnetic properties and structure of hemoglobin, oxyhemoglobin and carbonmonoxyhemoglobin. Proc Natl Acad Sci USA. 1936;22:210–6.CrossRef
17.
go back to reference Pauling L. Magnetic properties and structure of oxyhemoglobin. Proc Natl Acad Sci USA. 1977;74:2612–3.CrossRef Pauling L. Magnetic properties and structure of oxyhemoglobin. Proc Natl Acad Sci USA. 1977;74:2612–3.CrossRef
18.
go back to reference Kumar S, Guha M, Choubey V, Maity P, Bandyopadhyay U. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update. Life Sci. 2007;80:813–28.CrossRef Kumar S, Guha M, Choubey V, Maity P, Bandyopadhyay U. Antimalarial drugs inhibiting hemozoin (beta-hematin) formation: a mechanistic update. Life Sci. 2007;80:813–28.CrossRef
19.
go back to reference Jaramillo M, Bellemare M-J, Martel C, Shio MT, Contreras AP, Godbout M, et al. Synthetic Plasmodium-like hemozoin activates the immune response: a morphology—function study. PLoS ONE. 2009;4:e6957-e.CrossRef Jaramillo M, Bellemare M-J, Martel C, Shio MT, Contreras AP, Godbout M, et al. Synthetic Plasmodium-like hemozoin activates the immune response: a morphology—function study. PLoS ONE. 2009;4:e6957-e.CrossRef
20.
go back to reference Huy NT, Uyen DT, Maeda A, Trang DTX, Oida T, Harada S, et al. Simple colorimetric inhibition assay of heme crystallization for high-throughput screening of antimalarial compounds. Antimicrob Agents Chemother. 2007;51:350–3.CrossRef Huy NT, Uyen DT, Maeda A, Trang DTX, Oida T, Harada S, et al. Simple colorimetric inhibition assay of heme crystallization for high-throughput screening of antimalarial compounds. Antimicrob Agents Chemother. 2007;51:350–3.CrossRef
21.
go back to reference Acharya BN, Saraswat D, Tiwari M, Shrivastava AK, Ghorpade R, Bapna S, et al. Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines. Eur J Med Chem. 2010;45:430–8.CrossRef Acharya BN, Saraswat D, Tiwari M, Shrivastava AK, Ghorpade R, Bapna S, et al. Synthesis and antimalarial evaluation of 1, 3, 5-trisubstituted pyrazolines. Eur J Med Chem. 2010;45:430–8.CrossRef
22.
go back to reference Andayi WA, Egan TJ, Gut J, Rosenthal PJ, Chibale K. Synthesis, antiplasmodial activity, and β-hematin inhibition of hydroxypyridone–chloroquine hybrids. ACS Med Chem Lett. 2013;4:642–6.CrossRef Andayi WA, Egan TJ, Gut J, Rosenthal PJ, Chibale K. Synthesis, antiplasmodial activity, and β-hematin inhibition of hydroxypyridone–chloroquine hybrids. ACS Med Chem Lett. 2013;4:642–6.CrossRef
23.
go back to reference Hawley SR, Bray PG, Mungthin M, Atkinson JD, O’Neill PM, Ward SA. Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1998;42:682–6.CrossRef Hawley SR, Bray PG, Mungthin M, Atkinson JD, O’Neill PM, Ward SA. Relationship between antimalarial drug activity, accumulation, and inhibition of heme polymerization in Plasmodium falciparum in vitro. Antimicrob Agents Chemother. 1998;42:682–6.CrossRef
24.
go back to reference Guetzoyan L, Yu X-M, Ramiandrasoa F, Pethe S, Rogier C, Pradines B, et al. Antimalarial acridines: synthesis, in vitro activity against P. falciparum and interaction with hematin. Bioorg Med Chem. 2009;17:8032–9.CrossRef Guetzoyan L, Yu X-M, Ramiandrasoa F, Pethe S, Rogier C, Pradines B, et al. Antimalarial acridines: synthesis, in vitro activity against P. falciparum and interaction with hematin. Bioorg Med Chem. 2009;17:8032–9.CrossRef
25.
go back to reference Acharya BN, Saraswat D, Kaushik MP. Pharmacophore based discovery of potential antimalarial agent targeting haem detoxification pathway. Eur J Med Chem. 2008;43:2840–52.CrossRef Acharya BN, Saraswat D, Kaushik MP. Pharmacophore based discovery of potential antimalarial agent targeting haem detoxification pathway. Eur J Med Chem. 2008;43:2840–52.CrossRef
26.
go back to reference Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004;74:1957–72.CrossRef Fitch CD. Ferriprotoporphyrin IX, phospholipids, and the antimalarial actions of quinoline drugs. Life Sci. 2004;74:1957–72.CrossRef
27.
go back to reference Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.CrossRef Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.CrossRef
28.
go back to reference Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47:46.CrossRef Tawfik GM, Dila KAS, Mohamed MYF, Tam DNH, Kien ND, Ahmed AM, et al. A step by step guide for conducting a systematic review and meta-analysis with simulation data. Trop Med Health. 2019;47:46.CrossRef
29.
go back to reference Schneider K, Schwarz M, Burkholder I, Kopp-Schneider A, Edler L, Kinsner-Ovaskainen A, et al. “ToxRTool”, a new tool to assess the reliability of toxicological data. Toxicol Lett. 2009;189:138–44.CrossRef Schneider K, Schwarz M, Burkholder I, Kopp-Schneider A, Edler L, Kinsner-Ovaskainen A, et al. “ToxRTool”, a new tool to assess the reliability of toxicological data. Toxicol Lett. 2009;189:138–44.CrossRef
30.
go back to reference Burgess SJ, Kelly JX, Shomloo S, Wittlin S, Brun R, Liebmann K, et al. Synthesis, structure–activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds. J Med Chem. 2010;53:6477–89.CrossRef Burgess SJ, Kelly JX, Shomloo S, Wittlin S, Brun R, Liebmann K, et al. Synthesis, structure–activity relationship, and mode-of-action studies of antimalarial reversed chloroquine compounds. J Med Chem. 2010;53:6477–89.CrossRef
31.
go back to reference Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998;55:727–36.CrossRef Dorn A, Vippagunta SR, Matile H, Jaquet C, Vennerstrom JL, Ridley RG. An assessment of drug-haematin binding as a mechanism for inhibition of haematin polymerisation by quinoline antimalarials. Biochem Pharmacol. 1998;55:727–36.CrossRef
32.
go back to reference Kaschula CH, Egan TJ, Hunter R, Basilico N, Parapini S, Taramelli D, et al. Structure–activity relationships in 4-aminoquinoline antiplasmodials. The role of the group at the 7-position. J Med Chem. 2002;45:3531–9.CrossRef Kaschula CH, Egan TJ, Hunter R, Basilico N, Parapini S, Taramelli D, et al. Structure–activity relationships in 4-aminoquinoline antiplasmodials. The role of the group at the 7-position. J Med Chem. 2002;45:3531–9.CrossRef
33.
go back to reference Sandlin RD, Fong KY, Wicht KJ, Carrell HM, Egan TJ, Wright DW. Identification of β-hematin inhibitors in a high-throughput screening effort reveals scaffolds with in vitro antimalarial activity. Int J Parasitol Drugs Drug Resist. 2014;4:316–25.CrossRef Sandlin RD, Fong KY, Wicht KJ, Carrell HM, Egan TJ, Wright DW. Identification of β-hematin inhibitors in a high-throughput screening effort reveals scaffolds with in vitro antimalarial activity. Int J Parasitol Drugs Drug Resist. 2014;4:316–25.CrossRef
34.
go back to reference Vennerstrom JL, Ager AL, Dorn A, Andersen SL, Gerena L, Ridley RG, et al. Bisquinolines. 2. Antimalarial N, N-bis (7-chloroquinolin-4-yl) heteroalkanediamines. J Med Chem. 1998;41:4360–4.CrossRef Vennerstrom JL, Ager AL, Dorn A, Andersen SL, Gerena L, Ridley RG, et al. Bisquinolines. 2. Antimalarial N, N-bis (7-chloroquinolin-4-yl) heteroalkanediamines. J Med Chem. 1998;41:4360–4.CrossRef
35.
go back to reference Ignatushchenko MV, Winter R, Bächinger HP, Hinrichs DJ, Riscoe MK. Xanthones as antimalarial agents; studies of a possible mode of action. FEBS Lett. 1997;409:67–73.CrossRef Ignatushchenko MV, Winter R, Bächinger HP, Hinrichs DJ, Riscoe MK. Xanthones as antimalarial agents; studies of a possible mode of action. FEBS Lett. 1997;409:67–73.CrossRef
36.
go back to reference Coronado LM, Nadovich CT, Spadafora C. Malarial hemozoin: from target to tool. Biochim Biophys Acta. 2014;1840:2032–41.CrossRef Coronado LM, Nadovich CT, Spadafora C. Malarial hemozoin: from target to tool. Biochim Biophys Acta. 2014;1840:2032–41.CrossRef
37.
go back to reference Fong KY, Wright DW. Hemozoin and antimalarial drug discovery. Future Med Chem. 2013;5:1437–50.CrossRef Fong KY, Wright DW. Hemozoin and antimalarial drug discovery. Future Med Chem. 2013;5:1437–50.CrossRef
38.
go back to reference Pulcini S, Staines HM, Lee AH, Shafik SH, Bouyer G, Moore CM, et al. Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite’s food vacuole and alter drug sensitivities. Sci Rep. 2015;5:14552.CrossRef Pulcini S, Staines HM, Lee AH, Shafik SH, Bouyer G, Moore CM, et al. Mutations in the Plasmodium falciparum chloroquine resistance transporter, PfCRT, enlarge the parasite’s food vacuole and alter drug sensitivities. Sci Rep. 2015;5:14552.CrossRef
Metadata
Title
Correlation between anti-malarial and anti-haemozoin activities of anti-malarial compounds
Authors
Dao Ngoc Hien Tam
Gehad Mohamed Tawfik
Amr Ehab El-Qushayri
Ghaleb Muhammad Mehyar
Sedralmontaha Istanbuly
Sedighe Karimzadeh
Vo Linh Tu
Ranjit Tiwari
Truong Van Dat
Phuong Thuy Viet Nguyen
Kenji Hirayama
Nguyen Tien Huy
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2020
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-020-03370-x

Other articles of this Issue 1/2020

Malaria Journal 1/2020 Go to the issue